- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04435327
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19) (SequelaeCov)
SequelaeCov: a Prospective Study on Lung Damage Caused by SARS-CoV-2 Pneumonia
Pneumonia is a recurrent element of COVID-19 infection, it is often associated with development of respiratory failure and patients frequently need various degrees of oxygen therapy up to non invasive ventilation (NIV-CPAP) and invasive mechanical ventilation (IMV).
Main purpose of this study is to evaluate with non invasive clinical instruments (pletysmography, Diffusion lung capacity for carbon monoxide -DLCO-, six minute walking test and dyspnea scores) and radiological tools (chest X-ray and chest CT scan) the development of medium-to-long term pulmonary sequelae caused by SARS-CoV-2 pneumonia.
Study Overview
Status
Detailed Description
SARS-CoV-2 related disease started in December 2019 in the Chinese city of Wuhan, rapidly spread and became an international health emergency.
Pneumonia is a frequent element of COVID-19, its pathogenic mechanisms are not entirely known and some patients develop various degrees of respiratory failure and need oxygen therapy up to NIV-CPAP) and IMV.
Some pathology studies in COVID-19 pneumonia show ARDS-like lesions associated to inflammatory reaction. It is known that pulmonary inflammatory damage can lead to fibrotic sequelae or to the development of pulmonary emphysema.
The main target of the study is to use non invasive methods (pletysmography, DLCO assessment, six minute walking test and dyspnea scores) and radiological tools (chest X-ray and chest CT scan) to identify pulmonary sequelae in patients hospitalised because of respiratory failure in COVID-19 pneumonia.
Study design: multicentre observational cohort study. Patients will be divided in three arms according to maximum ventilatory/oxygen support received during hospital stay:
- patients who received only oxygen therapy
- patients who received non invasive ventilation (NIV-CPAP)
- patients who received invasive mechanical ventilation (IMV)
All patients undergo a clinical evaluation at 6 months from hospital discharge (T1) and a second clinical evaluation at 12 months from hospital discharge (T2).
During (T1) patients undergo spirometry with pletysmography and DLCO assessment, six minute walking test, standard chest X-ray, arterial blood gas analysis if SaO2 < 93% in room air, dyspnea score and presence and extension of lung sounds at pulmonary auscultation.
During (T2) patients will undergo spirometry with pletysmography and DLCO assessment, six minute walking test, High Resolution CT scan (HRTC) of the thorax, arterial blood gas analysis if SaO2 < 93% in room air, dyspnea score and presence and extension of lung sounds at pulmonary auscultation).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
MB
-
Monza, MB, Italy, 20900
- San Gerardo Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18 and ≤ 80 years
- Able to sign informed consent to participate in the study
- Real time PCR diagnosis od SARS-CoV-2 infection
- Hospital admission due to clinical/instrumental diagnosis of interstitial pneumonia
- Presence of acute respiratory failure (PaO2/FiO2 <300 mm Hg) at the moment of hospital admission
Exclusion Criteria:
- Severe renal failure defined as glomerular filtration rate (GFR) < 30 ml/min at hospital discharge
- Cardiovascular failure NYHA class IV (patient unable to perform any activity) at hospital discharge
- Active solid or hematological malignancies at hospital discharge
- Prior diagnosis of chronic obstructive pulmonary disease (COPD), pulmonary emphysema, pulmonary fibrosis, bronchiectasis associated or not associated to cystic fibrosis
- Pregnancy or breastfeeding
- Suspected bacterial or fungine pulmonary superinfection during hospital stay
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Oxygen therapy
Patients who were hospitalised due to COVID-19 pneumonia and received only oxygen support therapy.
|
Non invasive ventilation (NIV/CPAP)
Patients who were hospitalised due to COVID-19 pneumonia and received non invasive ventilation (NIV/CPAP) as maximum support therapy
|
Invasive ventilation
Patients who were hospitalised due to COVID-19 pneumonia and received invasive mechanical ventilation (IMV)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction of Diffusion of Lung CO (DLCO, single breath technique)
Time Frame: T1 at 6 months from discharge
|
Reduction below 80% of predicted values of DLCO
|
T1 at 6 months from discharge
|
Reduction of Diffusion of Lung CO (DLCO, single breath technique)
Time Frame: T2 at 12 months from discharge
|
Reduction below 80% of predicted values of DLCO
|
T2 at 12 months from discharge
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alterations in 6 minute walking test (6MWT)
Time Frame: T1 at 6 months from discharge
|
reduction in maximum distance walked
|
T1 at 6 months from discharge
|
Alterations in 6 minute walking test (6MWT)
Time Frame: T2 at 12 months from discharge
|
reduction in maximum distance walked
|
T2 at 12 months from discharge
|
Alterations in 6 minute walking test (6MWT)
Time Frame: T1 at 6 months from discharge
|
reduction in oxygen saturation nadir
|
T1 at 6 months from discharge
|
Alterations in 6 minute walking test (6MWT)
Time Frame: T2 at 12 months from discharge
|
reduction in oxygen saturation nadir
|
T2 at 12 months from discharge
|
Alterations of pletismography
Time Frame: T1 at 6 months from discharge
|
reduction of Forced Vital Capacity (FVC, %)
|
T1 at 6 months from discharge
|
Alterations of pletismography
Time Frame: T2 at 12 months from discharge
|
reduction of Forced Vital Capacity (FVC, %)
|
T2 at 12 months from discharge
|
Alterations of pletismography
Time Frame: T1 at 6 months from discharge
|
reduction of Forced Vital Capacity (FVC, L)
|
T1 at 6 months from discharge
|
Alterations of pletismography
Time Frame: T2 at 12 months from discharge
|
reduction of Forced Vital Capacity (FVC, L)
|
T2 at 12 months from discharge
|
Alterations of pletismography
Time Frame: T1 at 6 months from discharge
|
reduction of Vital Capacity (VC, %)
|
T1 at 6 months from discharge
|
Alterations of pletismography
Time Frame: T2 at 12 months from discharge
|
reduction of Vital Capacity (VC, %)
|
T2 at 12 months from discharge
|
Alterations of pletismography
Time Frame: T1 at 6 months from discharge
|
reduction of Vital Capacity (VC, L)
|
T1 at 6 months from discharge
|
Alterations of pletismography
Time Frame: T2 at 12 months from discharge
|
reduction of Vital Capacity (VC, L)
|
T2 at 12 months from discharge
|
Alterations of pletismography
Time Frame: T1 at 6 months from discharge
|
reduction of Forced Expiratory Volume in the 1st second (FEV1, L)
|
T1 at 6 months from discharge
|
Alterations of pletismography
Time Frame: T1 at 6 months from discharge
|
reduction of Forced Expiratory Volume in the 1st second (FEV1, %)
|
T1 at 6 months from discharge
|
Alterations of pletismography
Time Frame: T2 at 12 months from discharge
|
reduction of Forced Expiratory Volume in the 1st second (FEV1, L)
|
T2 at 12 months from discharge
|
Alterations of pletismography
Time Frame: T2 at 12 months from discharge
|
reduction of Forced Expiratory Volume in the 1st second (FEV1, L%)
|
T2 at 12 months from discharge
|
Alterations of pletismography
Time Frame: T1 at 6 months from discharge
|
reduction of Total Lung Capacity (TLC, L)
|
T1 at 6 months from discharge
|
Alterations of pletismography
Time Frame: T1 at 6 months from discharge
|
reduction of Total Lung Capacity (TLC, %)
|
T1 at 6 months from discharge
|
Alterations of pletismography
Time Frame: T2 at 12 months from discharge
|
reduction of Total Lung Capacity (TLC, L)
|
T2 at 12 months from discharge
|
Alterations of pletismography
Time Frame: T2 at 12 months from discharge
|
reduction of Total Lung Capacity (TLC, %)
|
T2 at 12 months from discharge
|
Alterations of pletismography
Time Frame: T1 at 6 months from discharge
|
alterations of Residual Volume (RV,%)
|
T1 at 6 months from discharge
|
Alterations of pletismography
Time Frame: T1 at 6 months from discharge
|
alterations of Residual Volume (RV, L)
|
T1 at 6 months from discharge
|
Alterations of pletismography
Time Frame: T2 at 12 months from discharge
|
alterations of Residual Volume (RV, L)
|
T2 at 12 months from discharge
|
Alterations of pletismography
Time Frame: T2 at 12 months from discharge
|
alterations of Residual Volume (RV, %)
|
T2 at 12 months from discharge
|
Alterations of pletismography
Time Frame: T1 at 6 months from discharge
|
increase of Specific Airway Resistance (sRAW) (absolute value)
|
T1 at 6 months from discharge
|
Alterations of pletismography
Time Frame: T1 at 6 months from discharge
|
increase of Specific Airway Resistance (sRAW) (%)
|
T1 at 6 months from discharge
|
Alterations of pletismography
Time Frame: T2 at 12 months from discharge
|
increase of Specific Airway Resistance (sRAW) (absolute value)
|
T2 at 12 months from discharge
|
Alterations of pletismography
Time Frame: T2 at 12 months from discharge
|
increase of Specific Airway Resistance (sRAW) (%)
|
T2 at 12 months from discharge
|
Alterations of pletismography
Time Frame: T1 at 6 months from discharge
|
alterations of Motley Index (VR/CPT)
|
T1 at 6 months from discharge
|
Alterations of pletismography
Time Frame: T2 at 12 months from discharge
|
alterations of Motley Index (VR/CPT)
|
T2 at 12 months from discharge
|
Alterations of pletismography
Time Frame: T1 at 6 months from discharge
|
alterations of Tiffeneau Index (IT)
|
T1 at 6 months from discharge
|
Alterations of pletismography
Time Frame: T2 at 12 months from discharge
|
alterations of Tiffeneau Index (IT)
|
T2 at 12 months from discharge
|
Alterations of Arterial Blood Gas Analysis
Time Frame: T1 at 6 months from discharge
|
reduction of PaO2 mmHg
|
T1 at 6 months from discharge
|
Alterations of Arterial Blood Gas Analysis
Time Frame: T2 at 12 months from discharge
|
reduction of PaO2 mmHg
|
T2 at 12 months from discharge
|
Alterations of Arterial Blood Gas Analysis
Time Frame: T1 at 6 months from discharge
|
alteration of PaCO2 mmHg
|
T1 at 6 months from discharge
|
Alterations of Arterial Blood Gas Analysis
Time Frame: T2 at 12 months from discharge
|
alteration of PaCO2 mmHg
|
T2 at 12 months from discharge
|
Abnormal Dyspnea Score
Time Frame: T1 at 6 months from discharge
|
Modified Medical Research Council - mMRC > 0 (minimum 0, maximum 4; higher score means worse outcome)
|
T1 at 6 months from discharge
|
Abnormal Dyspnea Score
Time Frame: T2 at 12 months from discharge
|
Modified Medical Research Council - mMRC > 0(minimum 0, maximum 4; higher score means worse outcome)
|
T2 at 12 months from discharge
|
Presence and extension of abnormal pulmonary lung sounds at auscultation
Time Frame: T1 at 6 months from discharge
|
Presence and extension of abnormal pulmonary lung sounds at auscultation
|
T1 at 6 months from discharge
|
Presence and extension of abnormal pulmonary lung sounds at auscultation
Time Frame: T2 at 12 months from discharge
|
Presence and extension of abnormal pulmonary lung sounds at auscultation
|
T2 at 12 months from discharge
|
Presence and extension of radiological alterations at chest X-ray
Time Frame: T1 at 6 months from discharge
|
Presence and extension of radiological alterations at chest X-ray
|
T1 at 6 months from discharge
|
Presence and extension of radiological alterations at chest CT scan
Time Frame: T2 at 12 months from discharge
|
Presence and extension of radiological alterations at chest CT scan
|
T2 at 12 months from discharge
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SequelaeCov
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia, Viral
-
Hospices Civils de LyonTerminatedCOVID-19 | Viral Pneumonia Human CoronavirusFrance
-
University of Texas Southwestern Medical CenterWithdrawnBacterial Pneumonia | Viral PneumoniaUnited States
-
Cairo UniversityUnknown
-
Zhong WangNot yet recruiting
-
Wecare Probiotics Co., Ltd.Not yet recruitingViral Pneumonia
-
Instituto Nacional de Ciencias Medicas y Nutricion...CompletedCoronavirus Infections | COVID-19 | Viral Pneumonia Human CoronavirusMexico
-
Francesco De CobelliCompleted
-
South Egypt Cancer InstituteRecruiting
-
University Hospital, LilleCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted